DANBURY, Conn., July 6 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company’s product candidates will be presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, U.S.A. next week.
Oral Presentation:
#51, Oral session on peptides and proteins, Monday July 12, 20104:00 PM (PT)“‘Smart’ Basal Insulin Formulation that Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine,” to be presented by N. Kashyap, Biodel Inc.
Poster Presentation:
#373, Poster session on peptides and proteins, Monday July 12, 20101:00 PM - 2:00 PM (PT) “Effect of EDTA Concentration on Ultra-Rapid Action of VIAject® in Diabetic Miniature Swine,” to be presented by Dr. R. Pohl, Biodel Inc.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel’s product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. Biodel’s new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company’s website at www.biodel.com.
BIOD-G
SOURCE Biodel Inc.
